Literature DB >> 22450979

Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes.

Mario Tumbarello1, Enrico Maria Trecarichi, Barbara Fiori, Angela Raffaella Losito, Tiziana D'Inzeo, Lara Campana, Alberto Ruggeri, Eugenia Di Meco, Elvira Liberto, Giovanni Fadda, Roberto Cauda, Teresa Spanu.   

Abstract

Our aims were to identify (i) risk factors associated with the acquisition of multidrug-resistant (MDR, to 3 or more classes of antimicrobials) Proteus mirabilis isolates responsible for bloodstream infections (BSIs) and (ii) the impact on mortality of such infections. Risk factors for acquiring MDR P. mirabilis BSIs were investigated in a case-case-control study; those associated with mortality were assessed by comparing survivors and nonsurvivors in a cohort study. The population consisted of 99 adult inpatients with P. mirabilis BSIs identified by our laboratory over an 11-year period (1999 to 2009), 36 (33.3%) of which were caused by MDR strains, and the overall 21-day mortality rate was 30.3%. Acquisition of an MDR strain was independently associated with admission from a long-term care facility (odds ratio [OR], 9.78; 95% confidence interval [CI], 1.94 to 49.16), previous therapy with fluoroquinolones (OR, 5.52; 95% CI, 1.30 to 23.43) or oxyimino-cephalosporins (OR, 4.72; 95% CI, 1.31 to 16.99), urinary catheterization (OR, 3.89; 95% CI, 1.50 to 10.09), and previous hospitalization (OR, 2.68; 95% CI, 10.4 to 6.89). Patients with MDR P. mirabilis BSIs received inadequate initial antimicrobial therapy (IIAT, i.e., treatment with drugs to which the isolate displayed in vitro resistance) more frequently than those with non-MDR infections; they also had increased mortality and (for survivors) longer post-BSI-onset hospital stays. In multivariate regression analysis, 21-day mortality was associated with septic shock at BSI onset (OR, 12.97; 95% CI, 32.2 to 52.23), P. mirabilis isolates that were MDR (OR, 6.62; 95% CI, 16.4 to 26.68), and IIAT (OR, 9.85; 95% CI, 26.7 to 36.25), the only modifiable risk factor of the 3. These findings can potentially improve clinicians' ability to identify P. mirabilis BSIs likely to be MDR, thereby reducing the risk of IIAT--a major risk factor for mortality in these cases--and facilitating the prompt implementation of appropriate infection control measures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22450979      PMCID: PMC3370815          DOI: 10.1128/AAC.05966-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 2.  The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance.

Authors:  Keith S Kaye; Anthony D Harris; Matthew Samore; Yehuda Carmeli
Journal:  Infect Control Hosp Epidemiol       Date:  2005-04       Impact factor: 3.254

3.  Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.

Authors:  Mario Tumbarello; Teresa Spanu; Maurizio Sanguinetti; Rita Citton; Eva Montuori; Fiammetta Leone; Giovanni Fadda; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Reduction of inappropriate urinary catheter use at a Veterans Affairs hospital through a multifaceted quality improvement project.

Authors:  Bettina M Knoll; Deborah Wright; LeAnn Ellingson; Linda Kraemer; Ronald Patire; Michael A Kuskowski; James R Johnson
Journal:  Clin Infect Dis       Date:  2011-06       Impact factor: 9.079

5.  Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities.

Authors:  Carl Urban; Noriel Mariano; Patricia A Bradford; Margareta Tuckman; Sorana Segal-Maurer; Wehbeh Wehbeh; Louise Grenner; Rita Colon-Urban; Brian Johnston; James R Johnson; James J Rahal
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

6.  Multidrug resistance to antimicrobials as a predominant factor influencing patient survival.

Authors:  Evangelos J Giamarellos-Bourboulis; Evangelia Papadimitriou; Nearchos Galanakis; Anastasia Antonopoulou; Thomas Tsaganos; Kyriaki Kanellakopoulou; Helen Giamarellou
Journal:  Int J Antimicrob Agents       Date:  2006-05-16       Impact factor: 5.283

7.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

8.  Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals.

Authors:  Joanna Empel; Anna Baraniak; Elzbieta Literacka; Agnieszka Mrówka; Janusz Fiett; Ewa Sadowy; Waleria Hryniewicz; Marek Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

9.  Molecular epidemiology of ESbetaL producing P. mirabilis strains from a long-term care and rehabilitation facility in Italy.

Authors:  Roberta Migliavacca; Anna Migliavacca; Elisabetta Nucleo; Anna Ciaponi; Melissa Spalla; Concetta De Luca; Laura Pagani
Journal:  New Microbiol       Date:  2007-07       Impact factor: 2.479

10.  The impact of antimicrobial resistance on health and economic outcomes.

Authors:  Sara E Cosgrove; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2003-05-16       Impact factor: 9.079

View more
  12 in total

1.  A Rare Opportunist, Morganella morganii, Decreases Severity of Polymicrobial Catheter-Associated Urinary Tract Infection.

Authors:  Brian S Learman; Aimee L Brauer; Kathryn A Eaton; Chelsie E Armbruster
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

2.  Genome Sequences of Two Multidrug-Resistant Proteus mirabilis Strains Harboring CTX-M-65 Isolated from Malaysia.

Authors:  Choo Yee Yu; Geik Yong Ang; Yun Fong Ngeow; Kok Keng Tee; Wai-Fong Yin; Kok-Gan Chan
Journal:  Genome Announc       Date:  2016-11-17

3.  The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.

Authors:  Jin Young Ahn; Hea Won Ann; Yongduk Jeon; Mi Young Ahn; Dong Hyun Oh; Yong Chan Kim; Eun Jin Kim; Je Eun Song; In Young Jung; Moo Hyun Kim; Wooyoung Jeong; Nam Su Ku; Su Jin Jeong; Jun Yong Choi; Dongeun Yong; Young Goo Song; June Myung Kim
Journal:  BMC Infect Dis       Date:  2017-05-03       Impact factor: 3.090

4.  Phenotypic Detection and Antibiogram of β-lactamase-producing Proteus Species in a Tertiary Care Hospital, India.

Authors:  N Pal; S Hooja; R Sharma; R K Maheshwari
Journal:  Ann Med Health Sci Res       Date:  2016 Sep-Oct

Review 5.  The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the Evidence.

Authors:  Sonali Coulter; Jason A Roberts; Krispin Hajkowicz; Kate Halton
Journal:  Infect Dis Rep       Date:  2017-03-30

6.  Twin arginine translocation, ammonia incorporation, and polyamine biosynthesis are crucial for Proteus mirabilis fitness during bloodstream infection.

Authors:  Chelsie E Armbruster; Valerie S Forsyth; Alexandra O Johnson; Sara N Smith; Ashley N White; Aimee L Brauer; Brian S Learman; Lili Zhao; Weisheng Wu; Mark T Anderson; Michael A Bachman; Harry L T Mobley
Journal:  PLoS Pathog       Date:  2019-04-22       Impact factor: 6.823

7.  Primary and Secondary Bacteremia Caused by Proteus spp.: Epidemiology, Strains Susceptibility and Biofilm Formation.

Authors:  Joanna Kwiecińska-Piróg; Krzysztof Skowron; Eugenia Gospodarek-Komkowska
Journal:  Pol J Microbiol       Date:  2018

8.  In vitro anti-biofilm activity of bacteriocin from a marine Bacillus sp. strain Sh10 against Proteus mirabilis.

Authors:  Fatemeh Shayesteh; Asmat Ahmad; Gires Usup
Journal:  Iran J Microbiol       Date:  2020-02

9.  Catalase Activity is Critical for Proteus mirabilis Biofilm Development, Extracellular Polymeric Substance Composition, and Dissemination during Catheter-Associated Urinary Tract Infection.

Authors:  Ashley N White; Brian S Learman; Aimee L Brauer; Chelsie E Armbruster
Journal:  Infect Immun       Date:  2021-07-19       Impact factor: 3.441

10.  High Prevalence of Multidrug-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Cross-Sectional Study at Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia.

Authors:  Adane Bitew; Estifanos Tsige
Journal:  J Trop Med       Date:  2020-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.